Belite Bio, Inc (BLTE)
NEGATIVEFondamental
~26
Prix
$162.31
Capitalisation boursière
$6.44B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Données financières limitées disponibles (33% des indicateurs). Les scores peuvent ne pas refléter fidèlement les fondamentaux de cette entreprise.
Bilan & Liquidités
Chiffre d'affaires
0
Exercice clos le 31/12/2025
Résultat net
$-78M
Exercice clos le 31/12/2025
Flux de trésorerie libre
-
Capitaux propres totaux
$777M
Passif total
0
Ratio de liquidité général
33.56
Couverture des intérêts
-
Dette/EBITDA
-
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$214.00
Prix actuel
$162.31
Marge de sécurité
+24.2%
Fourchette de juste valeur
$203.30 - $224.70
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
-
ROE
-22.1%
Ratio P/B
8.11
P/FCF
-
Marge brute
0.0%
ROIC
-
Radar de rentabilité
Value Creation (Economic Moat)
ROIC
-
WACC
8.0%
ROIC − WACC
-
Critères d'analyse fondamentale
Réussi (3)
- Price CAGR 52.03%
- Current Ratio
- Analyst Consensus 93% Buy
Échoué (6)
- Gross Margin 0.0%
- P/B Ratio 8.11
- DCF valuation (Unknown)
- ROE -26.9%
- Earnings Surprise avg -19.7%
- Piotroski F-Score 0/9
Indisponible (18)
- EPS data insufficient
- ROIC NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- Operating Margin NaN%
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Share Dilution (missing shares data)
- Net Margin Trend (invalid data)
Score F de Piotroski
Préoccupations financières sérieuses
Qualité des bénéfices
Qualité faible : examiner la comptabilité
Dilution du capital
Rachat d'actions. Favorable aux actionnaires
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Dr. Yu-Hsin Lin M.B.A., Ph.D. | Chairman of the Board of Directors & CEO | 47 |
| Mr. Hao-Yuan Chuang C.F.A., F.R.M., M.B.A. | CFO & Director | 41 |
| Dr. Nathan L. Mata Ph.D. | Chief Scientific Officer | 59 |
| Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D. | Chief Medical Officer | 56 |
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Latest News
Recent headlines for BLTE, sourced from Markets Gazette.
- 3/3/2026NEUTRALBelite Bio (BLTE) Q4 2025 Earnings Call Transcript
Belite Bio (BLTE) investors are awaiting crucial details following the announcement of the Q4 2025 earnings call transcript. Although the event was reported, the actual content of the transcript is not yet available. This lack of information prevents analysts and investors from assessing the company's financial performance, future outlook, or any significant announcements that could impact the stock's value. Transparency is key for the market, and the absence of concrete data keeps the stock in a phase of uncertainty, with operators eagerly awaiting details to formulate forecasts and make informed decisions.
via Markets Gazette